Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT05411835

Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders

Safety and Tolerability of Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders

Sponsor: Oregon Health and Science University

Conditions Carnitine Palmitoyltransferase Deficiency 2 Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency Trifunctional Protein Deficiency Very Long Chain Acyl Coa Dehydrogenase Deficiency

Interventions Isocaloric Placebo Supplement Nutritional Ketone Supplement

Updated 5 times since 2022 Last updated: Apr 1, 2024 Started: Aug 1, 2022 Primary completion: Jan 31, 2023 Completion: Jan 22, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Carnitine Palmitoyltransferase Deficiency 2 and Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency and is currently completed. Oregon Health and Science University leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
May 2024 — Jul 2024 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed
Nov 2022 — May 2024 [monthly]

Recruiting EARLY_PHASE1

Status: Not Yet Recruiting → Recruiting
Jul 2022 — Nov 2022 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oregon Health and Science University

Data source: Oregon Health and Science University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States